메뉴 건너뛰기




Volumn 39, Issue 1, 2013, Pages 113-117

Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types

Author keywords

Antiemetic; Aprepitant; Chemotherapy induced nausea and vomiting; Highly emetogenic chemotherapy; Moderately emetogenic chemotherapy

Indexed keywords

APREPITANT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; ONDANSETRON; OXALIPLATIN;

EID: 84869081205     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.09.002     Document Type: Review
Times cited : (23)

References (20)
  • 1
    • 77956458957 scopus 로고    scopus 로고
    • Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy
    • Hesketh P.J., Aapro M., Street J.C., Carides A.D. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 2010, 18:1171-1177.
    • (2010) Support Care Cancer , vol.18 , pp. 1171-1177
    • Hesketh, P.J.1    Aapro, M.2    Street, J.C.3    Carides, A.D.4
  • 2
    • 0032992455 scopus 로고    scopus 로고
    • Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice
    • Hesketh P.J. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 1999, 4:191-196.
    • (1999) Oncologist , vol.4 , pp. 191-196
    • Hesketh, P.J.1
  • 3
    • 77954345456 scopus 로고    scopus 로고
    • Testicular seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
    • Schmoll H.J., Jordan K., Huddart R., et al. Testicular seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21:v140-v146.
    • (2010) Ann Oncol , vol.21
    • Schmoll, H.J.1    Jordan, K.2    Huddart, R.3
  • 4
    • 77954322183 scopus 로고    scopus 로고
    • Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
    • Okines A., Verheij M., Allum W., Cunningham D., Cervantes A. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21:v50-v54.
    • (2010) Ann Oncol , vol.21
    • Okines, A.1    Verheij, M.2    Allum, W.3    Cunningham, D.4    Cervantes, A.5
  • 5
    • 77954340426 scopus 로고    scopus 로고
    • Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
    • Colombo N., Peiretti M., Parma G., et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21:v23-v30.
    • (2010) Ann Oncol , vol.21
    • Colombo, N.1    Peiretti, M.2    Parma, G.3
  • 6
    • 77954319884 scopus 로고    scopus 로고
    • Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
    • Haie-Meder C., Morice P., Castiglione M. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21:v37-v40.
    • (2010) Ann Oncol , vol.21
    • Haie-Meder, C.1    Morice, P.2    Castiglione, M.3
  • 7
    • 0347816226 scopus 로고    scopus 로고
    • The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the aprepitant protocol 052 study group
    • Hesketh P.J., Grunberg S.M., Gralla R.J., et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the aprepitant protocol 052 study group. J Clin Oncol 2003, 21:4112-4119.
    • (2003) J Clin Oncol , vol.21 , pp. 4112-4119
    • Hesketh, P.J.1    Grunberg, S.M.2    Gralla, R.J.3
  • 8
    • 0038728753 scopus 로고    scopus 로고
    • Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America
    • Poli-Bigelli S., Rodrigues-Pereira J., Carides A.D., et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003, 97:3090-3098.
    • (2003) Cancer , vol.97 , pp. 3090-3098
    • Poli-Bigelli, S.1    Rodrigues-Pereira, J.2    Carides, A.D.3
  • 9
    • 21044434743 scopus 로고    scopus 로고
    • Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy
    • Warr D.G., Hesketh P.J., Gralla R.J., et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005, 23:2822-2830.
    • (2005) J Clin Oncol , vol.23 , pp. 2822-2830
    • Warr, D.G.1    Hesketh, P.J.2    Gralla, R.J.3
  • 10
    • 33745515076 scopus 로고    scopus 로고
    • American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006
    • Kris M.G., Hesketh P.J., Somerfield M.R., et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006, 24:2932-2947.
    • (2006) J Clin Oncol , vol.24 , pp. 2932-2947
    • Kris, M.G.1    Hesketh, P.J.2    Somerfield, M.R.3
  • 11
    • 77954319603 scopus 로고    scopus 로고
    • Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference
    • Roila F., Herrstedt J., Aapro M., et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010, 21:v232-v243.
    • (2010) Ann Oncol , vol.21
    • Roila, F.1    Herrstedt, J.2    Aapro, M.3
  • 12
    • 84870494170 scopus 로고    scopus 로고
    • National Comprehensive Cancer Network. Clinical practice guidelines in oncology - V.1.2012: antiemesis. Available from:
    • National Comprehensive Cancer Network. Clinical practice guidelines in oncology - V.1.2012: antiemesis. Available from: http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.
  • 13
    • 77952480785 scopus 로고    scopus 로고
    • Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study
    • Rapoport B.L., Jordan K., Boice J.A., et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 2010, 18:423-431.
    • (2010) Support Care Cancer , vol.18 , pp. 423-431
    • Rapoport, B.L.1    Jordan, K.2    Boice, J.A.3
  • 14
    • 20444482460 scopus 로고    scopus 로고
    • The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials
    • Warr D.G., Grunberg S.M., Gralla R.J., et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 2005, 41:1278-1285.
    • (2005) Eur J Cancer , vol.41 , pp. 1278-1285
    • Warr, D.G.1    Grunberg, S.M.2    Gralla, R.J.3
  • 15
    • 80755126820 scopus 로고    scopus 로고
    • Antiemetics: American Society of Clinical Oncology clinical practice guideline update
    • Basch E., Prestrud A.A., Hesketh P.J., et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011, 29:4189-4198.
    • (2011) J Clin Oncol , vol.29 , pp. 4189-4198
    • Basch, E.1    Prestrud, A.A.2    Hesketh, P.J.3
  • 16
    • 84869083097 scopus 로고    scopus 로고
    • Aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic (MEC) chemotherapy in patients with breast cancer
    • [Abstract 1116]
    • Webb T., Hardwick J., Carides A.D., Street J.C. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic (MEC) chemotherapy in patients with breast cancer. Cancer Res 2010, 69. [Abstract 1116].
    • (2010) Cancer Res , vol.69
    • Webb, T.1    Hardwick, J.2    Carides, A.D.3    Street, J.C.4
  • 17
    • 33646412299 scopus 로고    scopus 로고
    • Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response
    • Hesketh P.J., Grunberg S.M., Herrstedt J., et al. Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 2006, 14:354-360.
    • (2006) Support Care Cancer , vol.14 , pp. 354-360
    • Hesketh, P.J.1    Grunberg, S.M.2    Herrstedt, J.3
  • 18
    • 80051582732 scopus 로고    scopus 로고
    • Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC)
    • Hesketh P.J., Warr D.G., Street J.C., Carides A.D. Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC). Support Care Cancer 2011, 19:1297-1302.
    • (2011) Support Care Cancer , vol.19 , pp. 1297-1302
    • Hesketh, P.J.1    Warr, D.G.2    Street, J.C.3    Carides, A.D.4
  • 19
    • 79951774253 scopus 로고    scopus 로고
    • Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist (NK1) aprepitant for all platinum agents: analysis of 1872 patients (pts) in prospective randomized clinical phase III trials (RCTs)
    • Gralla R.J., Rapoport B.L., Jordan K., Street J.C., Carides A. Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist (NK1) aprepitant for all platinum agents: analysis of 1872 patients (pts) in prospective randomized clinical phase III trials (RCTs). J Clin Oncol 2010, 28:9057.
    • (2010) J Clin Oncol , vol.28 , pp. 9057
    • Gralla, R.J.1    Rapoport, B.L.2    Jordan, K.3    Street, J.C.4    Carides, A.5
  • 20
    • 84863446959 scopus 로고    scopus 로고
    • Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy
    • Hesketh P.J., Sanz-Altamira P., Bushey J., Hesketh A.M. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Support Care Cancer 2012, 20:1043-1047.
    • (2012) Support Care Cancer , vol.20 , pp. 1043-1047
    • Hesketh, P.J.1    Sanz-Altamira, P.2    Bushey, J.3    Hesketh, A.M.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.